SCHEMBL7135487

SCHEMBL7135487

CCCCCCCCCCCCOC(CCCCCCCCCCC)CCOS(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MMP9 P14780 1/20 0.45
ALOX15 P16050 1/20 0.45
DNM1 Q05193 1/20 0.44
CA1 P00915 9/20 0.42
CA2 P00918 9/20 0.42
CA9 Q16790 8/20 0.42
CA12 O43570 3/20 0.42
CA7 P43166 3/20 0.42
CA14 Q9ULX7 3/20 0.42
CA3 P07451 2/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
RECQL P46063 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135483 1.00 TSHR (0.45) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL18720002 0.87 TSHR (0.45) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL17117078 0.86 TSHR (0.35) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL9677047 0.83 TSHR (0.43) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL18051492 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1
SCHEMBL11189857 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1
SCHEMBL5532689 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1
SCHEMBL17263911 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1
SCHEMBL11181978 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1
SCHEMBL11187145 0.82 DNM1 (0.61) TSHRALDH1A1LMNADNM1LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6511965-B2 For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia SANKYO COMPANY, LIMITED (JP) 2003-01-28 US disclosed
US-20020161221-A1 Ether type lipid a 1-carboxylic acid analogs SANKYO COMPANY, LIMITED (JP) 2002-10-31 US disclosed
EP-1152007-A1 ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES Sankyo Company, Limited (JP) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161221-A1 Ether type lipid a 1-carboxylic acid analogs MSR1, ELOVL1, FFAR1 TSHR 1487/4885KDM4E 630/4885USP2 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.